The only reason to take on a partner for this drug, or any drug for that matter, is to share risk. There is virtually no risk with Tedizolid so why would you as an investor want to share revenue with another company. Doesn't make financial sense. This platform has multibillion dollar revenues written all over it. TRius already has an ex-US/ex-South Korean deal with Bayer.
I agree, TSRX would make a nice add-on to a small biotech, or Ted a nice new product for a Pfizer. The cost and complexity of developing marketing, sales, managed markets/market access, manufacturing, distribution...is high. If they can find a partner, or buyer that will pay a reasonable price, it makes sense to partner, or sell. Take the money and run!
The pipeline besides TED is years away from the market. and sales of TED could be as low as $400M or as High as $1B. So why take on all the expense and complexity of becoming a Sales and Marketing Biotech. To detail a single drug is an expensive proposition.